Dr. Handelin is a veteran molecular, medical geneticist who has pioneered the responsible application of genetics to clinical medicine over a 30-year career. In 1987 Dr. Handelin established one of the first commercial DNA testing laboratories at Integrated Genetics (now Genzyme Genetics). After co-founding a gene therapy company (Genovo), Dr. Handelin began her own consulting practice, delivering to venture capital investors, start-ups, biomedical universities, biotechnology, diagnostics, genomics, pharmacogenomics and bioinformatics companies. She founded a biosimulation company, Kenna Technologies, where she has served as CEO until its acquisition by DNA Print Genomics. At DNAG she led the development of new pharmacogenetics diagnostic tests as well as bringing DNA identity technology to intelligence and forensic criminal investigations. In 2014 she cofounded the nonprofit organization, BioPontis Alliance for Rare Diseases, offering a nontraditional model for drug discovery in rare, orphan diseases. Today she is leading Audacity Therapeutics, PBC, and Audacity R4 Pharmaceutical Fund, proposing a new business model in the biopharmaceutical industry designed to reorient medical value ahead of financial returns. She also serves the research management needs of rare disease patient organizations through NovoKen, LLC. Dr. Handelin served on the boards of several genomics companies (e.g. EXACT Sciences and RedPath Integrated Pathology). She served 10 years as a board member of Public Responsibility in Medicine and Research (PRIM&R) as well as on a variety of federal committees and advisory panels on ethics in genetic testing, including the Secretary’s Advisory Panel on Genetics, Health and Society.

Don Hardison brings a broad private and public company background in both emerging and Fortune 500 companies. Mr. Hardison is currently President, CEO and Director of Biotheranostics, Inc. In the past, he was the President, CEO and Director of Good Start Genetics, Inc., a leading molecular diagnostics and information company, specializing in genetic screening for inherited disorders utilizing a proprietary next-generation sequencing platform. Prior to joining Good Start Genetics, he was an Executive Vice President & Chief Operating Officer at Laboratory Corporation of America Holdings (NYSE: LH) in Burlington, North Carolina. Don has served as President, CEO and Director of EXACT Sciences Corporation (NASDAQ: EXAS). Over the past 35 years, he also has worked as a Managing Partner of OnTarget, a sales and marketing consulting firm, and has held numerous leadership roles at Quest Diagnostics and SmithKline Beecham Corporation (GlaxoSmithKline). He currently serves on the Boards of HTG Molecular, Decode Health, Seventh Sense Biosystems, and The Isthmus Foundation. He holds a bachelor’s degree from the University of North Carolina, Chapel Hill.